Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

CRSP

Live52w high -35.7%

Core line items from CRSP's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Entity: CRISPR THERAPEUTICS AG·Source: SEC EDGAR companyfacts

Metric	Annual 2025 2025-12-31	Annual 2024 2024-12-31	Annual 2023 2023-12-31	Annual 2022 2022-12-31
Revenue	$3.51M	$37.31M	$371.21M	$1.20M
Operating Income	$-664.57M	$-466.57M	$-222.54M	$-673.16M
Net Income	$-581.60M	$-366.25M	$-153.61M	$-650.17M
EPS (Diluted)	$-6.47	$-4.34	$-1.94	$-8.36
Total Assets	$2.27B	$2.24B	$2.23B	$2.24B
Total Liabilities	$343.43M	$309.95M	$346.77M	$367.58M
Cash & Equivalents	$347.56M	$298.26M	$389.48M	$211.88M
Free Cash Flow OCF − CapEx	$-345.93M	$-144.68M	$-269.85M	$-532.93M
Shares Outstanding	95.89M	85.74M	80.04M	78.51M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data.

Core line items from CRSP's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w high -35.7%

Entity: CRISPR THERAPEUTICS AG·Source: SEC EDGAR companyfacts

Metric	Annual 2025 2025-12-31	Annual 2024 2024-12-31	Annual 2023 2023-12-31	Annual 2022 2022-12-31
Revenue	$3.51M	$37.31M	$371.21M	$1.20M
Operating Income	$-664.57M	$-466.57M	$-222.54M	$-673.16M
Net Income	$-581.60M	$-366.25M	$-153.61M	$-650.17M
EPS (Diluted)	$-6.47	$-4.34	$-1.94	$-8.36
Total Assets	$2.27B	$2.24B	$2.23B	$2.24B
Total Liabilities	$343.43M	$309.95M	$346.77M	$367.58M
Cash & Equivalents	$347.56M	$298.26M	$389.48M	$211.88M
Free Cash Flow OCF − CapEx	$-345.93M	$-144.68M	$-269.85M	$-532.93M
Shares Outstanding	95.89M	85.74M	80.04M	78.51M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data.